☰

Lucie Hamel, Ph.D. - Publications

Affiliations: 
2004 Université de Montréal, Montréal, Canada 
Area:
Oncology, Molecular Biology
Tree Info Similar researchers PubMed Report error

21 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Derderian S, Benidir T, Scarlata E, Altaylouni T, Hamel L, Zouanat FZ, Brimo F, Aprikian A, Chevalier S. Cell-by-cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression. The Journal of Pathology. Clinical Research. PMID 37073437 DOI: 10.1002/cjp2.319  0.741
2023 Ebrahimizadeh W, Guérard KP, Rouzbeh S, Scarlata E, Brimo F, Patel PG, Jamaspishvili T, Hamel L, Aprikian AG, Lee AY, Berman DM, Bartlett JMS, Chevalier S, Lapointe J. A DNA copy number alteration classifier as a prognostic tool for prostate cancer patients. British Journal of Cancer. PMID 37037938 DOI: 10.1038/s41416-023-02236-8  0.698
2022 Derderian S, Vesval Q, Wissing MD, Hamel L, Côté N, Vanhuyse M, Ferrario C, Bladou F, Aprikian A, Chevalier S. Liquid biopsy-based targeted gene screening highlights tumor cell subtypes in patients with advanced prostate cancer. Clinical and Translational Science. PMID 36172886 DOI: 10.1111/cts.13372  0.645
2022 Bramhecha YM, Guérard KP, Audet-Walsh É, Rouzbeh S, Kassem O, Pernet E, Scarlata E, Hamel L, Brimo F, Divangahi M, Aprikian AG, Chevalier S, Giguère V, Lapointe J. Fatty acid oxidation enzyme Δ3, Δ2-enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients. Oncogene. PMID 35411033 DOI: 10.1038/s41388-022-02276-z  0.702
2019 Aprikian S, Luz M, Brimo F, Scarlata E, Hamel L, Cury FL, Tanguay S, Aprikian AG, Kassouf W, Chevalier S. Improving ultrasound-based prostate volume estimation. Bmc Urology. 19: 68. PMID 31340802 DOI: 10.1186/S12894-019-0492-2  0.702
2018 Bramhecha YM, Rouzbeh S, Guérard KP, Scarlata E, Brimo F, Chevalier S, Hamel L, Aprikian AG, Lapointe J. The combination of PTEN deletion and 16p13.3 gain in prostate cancer provides additional prognostic information in patients treated with radical prostatectomy. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc. PMID 30140035 DOI: 10.1038/S41379-018-0107-6  0.684
2017 Bramhecha YM, Guérard KL, Rouzbeh S, Scarlata EM, Brimo F, Chevalier SMA, Hamel L, Dragomir A, Aprikian A, Lapointe J. Genomic Gain of 16p13.3 in Prostate Cancer Predicts Poor Clinical Outcome After Surgical Intervention. Molecular Cancer Research : McR. PMID 28993510 DOI: 10.1158/1541-7786.Mcr-17-0270  0.657
2017 Audet-Walsh É, Dufour CR, Yee T, Zouanat FZ, Yan M, Kalloghlian G, Vernier M, Caron M, Bourque G, Scarlata E, Hamel L, Brimo F, Aprikian AG, Lapointe J, Chevalier S, et al. Nuclear mTOR acts as a transcriptional integrator of the androgen signaling pathway in prostate cancer. Genes & Development. PMID 28724614 DOI: 10.1101/Gad.299958.117  0.682
2017 Rochette A, Boufaied N, Scarlata E, Hamel L, Brimo F, Whitaker HC, Ramos-Montoya A, Neal DE, Dragomir A, Aprikian A, Chevalier S, Thomson AA. Asporin is a stromally expressed marker associated with prostate cancer progression. British Journal of Cancer. PMID 28152543 DOI: 10.1038/Bjc.2017.15  0.736
2017 Altaylouni T, Zouanat F, Scarlata E, Benidir T, Hamel L, Brimo F, Bégin L, Aprikian A, Chevalier S. PD65-12 THE ANDROGEN RECEPTOR BECOMES A NOVEL PREDICTIVE BIOMARKER OF PROSTATE CANCER PROGRESSION WHEN POST TRANSLATIONALLY ACTIVATED BY THE FER KINASE ON TYROSINE 223 Journal of Urology. 197. DOI: 10.1016/J.Juro.2017.02.2962  0.721
2015 Abeshouse A, Ahn J, Akbani R, Ally A, Amin S, Andry CD, Annala M, Aprikian A, Armenia J, Arora A, Auman JT, Balasundaram M, Balu S, Barbieri CE, Bauer T, ... ... Hamel L, et al. The Molecular Taxonomy of Primary Prostate Cancer Cell. 163: 1011-1025. DOI: 10.1016/j.cell.2015.10.025  0.577
2013 Brimo F, Aprikian A, Latour M, Têtu B, Doueik A, Scarlata E, Hamel L, McKercher G, Saad F, Lacombe L, Carmel M, Chevalier S. Strategies for biochemical and pathologic quality assurance in a large multi-institutional biorepository; The experience of the PROCURE Quebec Prostate Cancer Biobank. Biopreservation and Biobanking. 11: 285-90. PMID 24194978 DOI: 10.1089/Bio.2013.0025  0.736
2013 Rocha J, Zouanat FZ, Zoubeidi A, Hamel L, Benidir T, Scarlata E, Brimo F, Aprikian A, Chevalier S. The Fer tyrosine kinase acts as a downstream interleukin-6 effector of androgen receptor activation in prostate cancer. Molecular and Cellular Endocrinology. 381: 140-9. PMID 23906537 DOI: 10.1016/J.Mce.2013.07.017  0.736
2013 Chevalier S, Cury FL, Scarlata E, El-Zayat E, Hamel L, Rocha J, Zouanat FZ, Moussa S, Scherz A, Elhilali M, Anidjar M. Endoscopic vascular targeted photodynamic therapy with the photosensitizer WST11 for benign prostatic hyperplasia in the preclinical dog model. The Journal of Urology. 190: 1946-53. PMID 23680311 DOI: 10.1016/J.Juro.2013.05.014  0.717
2012 Anidjar M, Scarlata E, Cury FL, Rocha J, Hamel L, Luz M, Chevalier S. Refining the orthotopic dog prostate cancer (DPC)-1 model to better bridge the gap between rodents and men. The Prostate. 72: 752-61. PMID 21882212 DOI: 10.1002/Pros.21479  0.737
2011 Chevalier S, Anidjar M, Scarlata E, Hamel L, Scherz A, Ficheux H, Borenstein N, Fiette L, Elhilali M. Preclinical study of the novel vascular occluding agent, WST11, for photodynamic therapy of the canine prostate. The Journal of Urology. 186: 302-9. PMID 21600602 DOI: 10.1016/J.Juro.2011.03.039  0.696
2010 Rocha J, Zouanat F, Zoubeidi A, Hamel L, Aprikian A, Chevalier S. 546 ANDROGEN RECEPTOR ACTIVATION BY THE FER KINASE IN PROSTATE CANCER Journal of Urology. 183. DOI: 10.1016/J.Juro.2010.02.766  0.782
2010 Luz M, Dal Pra A, Chevalier S, Aprikian A, Scarlata E, Hamel L, Cury F. Prostate Volume Assessment Prior Brachytherapy Implant - How Accurate is Trans-rectal Ultrasound? International Journal of Radiation Oncology*Biology*Physics. 78: S374-S375. DOI: 10.1016/J.Ijrobp.2010.07.883  0.701
2009 Zoubeidi A, Rocha J, Zouanat FZ, Hamel L, Scarlata E, Aprikian AG, Chevalier S. The Fer tyrosine kinase cooperates with interleukin-6 to activate signal transducer and activator of transcription 3 and promote human prostate cancer cell growth. Molecular Cancer Research : McR. 7: 142-55. PMID 19147545 DOI: 10.1158/1541-7786.Mcr-08-0117  0.799
2002 Chevalier S, Defoy I, Lacoste J, Hamel L, Guy L, Bégin LR, Aprikian AG. Vascular endothelial growth factor and signaling in the prostate: more than angiogenesis. Molecular and Cellular Endocrinology. 189: 169-79. PMID 12039075 DOI: 10.1016/S0303-7207(01)00728-6  0.747
2000 Wong SH, Hamel L, Chevalier S, Philip A. Endoglin expression on human microvascular endothelial cells association with betaglycan and formation of higher order complexes with TGF-beta signalling receptors. European Journal of Biochemistry / Febs. 267: 5550-60. PMID 10951214 DOI: 10.1046/j.1432-1327.2000.01621.x  0.504
Show low-probability matches.